Disclosed is an oral pharmaceutical formulation in the form of a granulate comprising more than 60% by weight of mesalazine or a pharmaceutically acceptable salt thereof, wherein said pharmaceutical formulation is packed in a sachet, capsule or blister package. Also disclosed is the use of mesalazine for the manufacture of the above pharmaceutical formulations comprising a total dosage amount of mesalazine chosen among the group consisting of: 0.5 g； 1.0 g； 1.5 g； 2 g； 3 g； 4g； 5 g； 6 g； 8 g, wherein the medicament is for the treatment of intestinal bowel disease.Foreliggende oppfinnelse er rettet mot en høy legemiddelformulering med ønskede egenskaper når det gjelder enkel fremstilling og visuelt utseende samt en pose for formuleringen.
